AC Immune SA Revenue | ACIU

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue AC Immune SA

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
3.57 M	27.3 M	14.8 M	3.94 M	-	15.4 M	110 M	6.91 M	20.3 M	23.2 M	39.1 M	30.3 M	-	-	-

All numbers in CHF currency

Indicator range from annual reports

Maximum	Minimum	Average
110 M	3.57 M	26.8 M

Quarterly Revenue AC Immune SA

2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q4	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.57 M	1.31 M	27.3 M	687 K	14.8 M	-	1 K	3.93 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.4 M	2.3 M	2.03 M	1.46 M	16.4 M	1.07 M	753 K	2.01 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in CHF currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
27.3 M	1 K	5.27 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Cytokinetics, Incorporated CYTK	88 M	$ 53.74	-3.26 %	$ 6.45 M	USA
Фармсинтез LIFE	372 M	-	-	-	Russia
Prothena Corporation plc PRTA	9.68 M	$ 7.93	0.51 %	$ 427 M	USA
Codiak BioSciences CDAK	22.9 M	-	-55.98 %	$ 2.15 M	USA
DBV Technologies S.A. DBVT	5.64 M	$ 10.54	7.55 %	$ 1.47 B	France
Regeneron Pharmaceuticals REGN	14.3 B	$ 904.69	0.2 %	$ 94.6 B	USA
DiaMedica Therapeutics DMAC	500 K	$ 9.47	4.76 %	$ 445 M	USA
Royalty Pharma plc RPRX	2.38 B	$ 67.31	-0.39 %	$ 28.9 B	USA
Checkpoint Therapeutics CKPT	41 K	-	-	$ 169 M	USA
Rhythm Pharmaceuticals RYTM	190 M	$ 111.51	6.18 %	$ 7.25 B	USA
Puma Biotechnology PBYI	228 M	$ 8.28	-15.25 %	$ 414 M	USA
SIGA Technologies SIGA	94.6 M	$ 3.12	4.55 %	$ 223 M	USA
Sage Therapeutics SAGE	41.2 M	-	-	$ 527 M	USA
Taro Pharmaceutical Industries Ltd. TARO	573 M	-	-	$ 1.62 B	Israel
Sol-Gel Technologies Ltd. SLGL	19.4 M	$ 61.62	-2.21 %	$ 172 M	Israel
SELLAS Life Sciences Group SLS	1 M	$ 8.41	6.73 %	$ 917 M	USA
Summit Therapeutics SMMT	705 K	$ 16.34	15.15 %	$ 12.2 B	Britain
Cabaletta Bio CABA	0.006	$ 1.3	1.17 %	$ 131 M	USA
Syndax Pharmaceuticals SNDX	172 M	$ 9.53	1.39 %	$ 826 M	USA
Sanofi SNY	37.4 B	$ 47.06	0.32 %	$ 57.4 B	France
Forma Therapeutics Holdings FMTX	7.44 M	-	-	$ 958 M	USA
Blueprint Medicines Corporation BPMC	509 M	-	-	$ 8.14 B	USA
Horizon Therapeutics Public Limited Company HZNP	3.63 B	-	-	$ 26.6 B	Irlanda
Sarepta Therapeutics SRPT	443 M	$ 17.8	0.68 %	$ 1.78 B	USA
Paratek Pharmaceuticals PRTK	160 M	-	-	$ 121 M	USA
China SXT Pharmaceuticals SXTC	1.14 M	$ 2.84	-3.07 %	$ 1.93 M	China
Takeda Pharmaceutical Company Limited TAK	4.58 T	$ 21.02	-0.92 %	$ 33.2 B	Japan
Tarsus Pharmaceuticals TARS	451 M	$ 68.11	0.87 %	$ 2.85 B	USA
ASLAN Pharmaceuticals Limited ASLN	3 M	-	-14.27 %	$ 1.7 M	Singapore
Bio-Techne Corporation TECH	1.22 B	$ 72.78	0.17 %	$ 11.4 B	USA
Teva Pharmaceutical Industries Limited TEVA	1.5 B	$ 42.32	1.33 %	$ 48.5 B	Israel
RedHill Biopharma Ltd. RDHL	8.04 M	$ 0.43	0.45 %	$ 5.3 B	Israel
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Unity Biotechnology UBX	236 K	-	-33.41 %	$ 3.37 M	USA
iTeos Therapeutics ITOS	35 M	-	-	$ 411 M	USA
Shattuck Labs STTK	1 M	$ 4.59	2.78 %	$ 319 M	USA
Seelos Therapeutics SEEL	2.2 M	-	-47.76 %	$ 6.27 M	USA
Evogene Ltd. EVGN	3.85 M	$ 0.28	-16.14 %	$ 2.2 M	Israel
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Protara Therapeutics TARA	2.95 M	$ 2.33	9.15 %	$ 99.8 M	USA
Galmed Pharmaceuticals Ltd. GLMD	2.04 M	$ 4.63	21.05 %	$ 20 M	Israel
Fennec Pharmaceuticals FENC	44.6 M	$ 9.79	4.26 %	$ 280 M	USA
Calithera Biosciences CALA	9.75 M	-	-10.95 %	$ 876 K	USA
United Therapeutics Corporation UTHR	3.18 B	$ 562.14	-0.63 %	$ 24.9 B	USA
Vericel Corporation VCEL	276 M	$ 54.56	5.36 %	$ 2.75 B	USA